Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups

被引:95
作者
Ailawadhi, Sikander [1 ]
Aldoss, Ibrahim T.
Yang, Dongyun [2 ]
Razavi, Pedram [2 ,3 ]
Cozen, Wendy [2 ,4 ]
Sher, Taimur [5 ]
Chanan-Khan, Asher [5 ]
机构
[1] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Div Hematol, Los Angeles, CA 90033 USA
[2] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90033 USA
[3] Univ So Calif, Dept Med, Los Angeles, CA 90033 USA
[4] Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA
[5] Mayo Clin, Div Hematol, Jacksonville, FL 32224 USA
关键词
multiple myeloma; ethnicity; Surveillance Epidemiology and End Results; Hispanic; outcome; HIGH-DOSE THERAPY; PLUS DEXAMETHASONE; SURVIVAL; RACE; TRANSPLANTATION; CHEMOTHERAPY; RISK; FEATURES; RESCUE; IMPACT;
D O I
10.1111/j.1365-2141.2012.09124.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Studies of ethnic disparities in malignancies have revealed variation in clinical outcomes. In multiple myeloma (MM), previous literature has focused only on patients of Caucasian and African-American (AA) descent. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of MM patients from a broader range of ethnicities, representing current United States demographics. The SEER 17 Registry data was utilized to analyse adult MM patients diagnosed since 1992 (n = 37 963), as patients of other ethnicities were not well represented prior to that. Overall survival (OS) and myeloma-specific survival (MSS) were compared across different ethnicities stratified by year of diagnosis, registry identification, age, sex and marital-status. Hispanics had the youngest median age at diagnosis (65 years) and Whites had the oldest (71 years) (P < 0.001). Increased age at diagnosis was an independent predictor of decreased OS and MSS. Asians had the best median OS (2.7 years) and MSS (4.1 years), while Hispanics had the worst median OS (2.4 years). These trends were more pronounced in patients =75 years. Cumulative survival benefit over successive years was largest among Whites (1.3 years) and smallest among Asians (0.5 years). These disparities may be secondary to multifactorial causes that need to be explored and should be considered for optimal triaging of healthcare resources.
引用
收藏
页码:91 / 98
页数:8
相关论文
共 30 条
[1]  
Abou-Jawde RM, 2006, HAEMATOLOGICA, V91, P1410
[2]  
[Anonymous], 2011, NAACCR GUID ENH HISP
[3]  
[Anonymous], J NCI
[4]  
[Anonymous], NCEST200903 US CENS
[5]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[6]   Survival of blacks and whites after a cancer diagnosis [J].
Bach, PB ;
Schrag, D ;
Brawley, OW ;
Galaznik, A ;
Yakren, S ;
Begg, CB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (16) :2106-2113
[7]   Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders [J].
Brown, Linda Morris ;
Gridley, Gloria ;
Check, David ;
Landgren, Ola .
BLOOD, 2008, 111 (07) :3388-3394
[8]   High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [J].
Child, JA ;
Morgan, GJ ;
Davies, FE ;
Owen, RG ;
Bell, SE ;
Hawkins, K ;
Brown, J ;
Drayson, MT ;
Selby, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1875-1883
[9]   Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [J].
Dimopoulos, Meletios ;
Spencer, Andrew ;
Attal, Michael ;
Prince, H. Miles ;
Harousseau, Jean-Luc ;
Dmoszynska, Anna ;
San Miguel, Jesus ;
Hellmann, Andrzej ;
Facon, Thierry ;
Foa, Robin ;
Corso, Alessandro ;
Masliak, Zvenyslava ;
Olesnyckyj, Marta ;
Yu, Zhinuan ;
Patin, John ;
Zeldis, Jerome B. ;
Knight, Robert D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2123-2132
[10]   High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial [J].
Fermand, JP ;
Ravaud, P ;
Chevret, S ;
Divine, M ;
Leblond, V ;
Belanger, C ;
Macro, M ;
Pertuiset, E ;
Dreyfus, F ;
Mariette, X ;
Boccacio, C ;
Brouet, JC .
BLOOD, 1998, 92 (09) :3131-3136